Plegridy is named as an intervention in 3 current clinical trials in our USA, Germany, France, Spain, Italy, Belgium, Czechia, Portugal, Turkey, Australia, Israel and Sweden registers. None are recruiting at the moment. The most common phase is Observational. The sponsor with the most trials is Biogen (2). The most-studied condition is Multiple Sclerosis, Relapsing-Remitting.
Of the three regulators tracked here, the first to approve Plegridy was the EU, on 18 Jul 2014. It is approved in 3 of the 3 regulators tracked here.
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis
NCT03958877 · Multiple Sclerosis, Relapsing-Remitting
|
Phase 3 | Active, closed | Biogen | USA, Germany, France, Spain, Italy, Belgium, Czechia, Portugal, Turkey, Australia, Israel |
|
A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies
NCT05688436 · ClinicalTrials.gov ↗ · Multiple Sclerosis
|
Observational | Active, closed | Biogen | USA |
|
An Observational Study to Learn About the Interferon-beta Exposure of Pregnant Women During the Second and Third Trimester in Finland and Sweden
NCT06053749 · ClinicalTrials.gov ↗ · Multiple Sclerosis (MS)
|
Observational | Active, closed | Bayer | Sweden |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Biogen | 2 |
| Bayer | 1 |
A trial with sites in more than one country appears in each of those registers.
3 current trials in our USA, Germany, France, Spain, Italy, Belgium, Czechia, Portugal, Turkey, Australia, Israel and Sweden registers name Plegridy (also registered as BIIB017) as a drug or biological intervention, as of the registry sync on 29 September 2026. Completed and withdrawn studies are not counted.
Not at the moment. None of the 3 trials in our registers is recruiting; they are active but closed to enrolment, not yet open, or enrolling by invitation. Only the study team can confirm whether a patient is eligible.
Biogen (2) and Bayer (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Plegridy works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Plegridy works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Plegridy (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 29 Sep 2026.